1
|
Nemola G, Russi A, Cozzani G, Leo G, Vetrugno L, Sparasci FM, Parlati AL, Della Bella P, Montorfano M, Tresoldi M, Salerno A, Cera M, Mattiello P, Comi G, Maisano F, Zangrillo A, Gaspardone C, Melillo F, Margonato A, Godino C. Baseline Characteristics and 3-Year Outcome of Nonvalvular Atrial Fibrillation Patients Treated with the Four Direct Oral Anticoagulants (DOACs). Am J Cardiol 2023; 206:125-131. [PMID: 37703678 DOI: 10.1016/j.amjcard.2023.07.181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/26/2023] [Revised: 07/25/2023] [Accepted: 07/31/2023] [Indexed: 09/15/2023]
Abstract
Direct oral anticoagulants (DOACs) represent the cornerstone therapy for cardioembolic events prevention in patients with nonvalvular atrial fibrillation (NVAF). In practice, the choice of one DOAC over another is guided by the decision-making process of the physician, which considers specific patient and drug characteristics. This study aimed to evaluate the clinical features and long-term outcomes of a real-world population treated with DOACs, where the use of the 4 different DOACs is quite equal. We conducted a retrospective observational, single-center, multidisciplinary study enrolling consecutive NVAF patients treated with one of the 4 DOACs. From an initial number of 753 patients, we excluded 72 patients because of loss to follow-up, at the end we enrolled 681:174 (23%) treated with dabigatran, 175 (23%) with apixaban, 190 (25%) with rivaroxaban, and 214 (29%) with edoxaban. Patients treated with apixaban were significantly older, more women represented (p <0.001), and with a higher cardioembolic and bleeding risk (p <0.001). Dabigatran was preferred in patients with liver failure (p = 0.008), whereas Apixaban and Edoxaban were chosen in chronic kidney disease (p = 0.002). At 3-year follow-up, 20 patients (2.7%) experienced a systemic thromboembolic event without significant differences in the 4 DOACs. In the same period, an International Society of Thrombosis and Hemostasis classification major bleeding event occurred in 26 patients (3.6%), more statistically correlated to edoxaban (6.1%) (p = 0.038). Thromboembolic events or major bleeding were higher in the edoxaban group (10%) compared with the others (p = 0.014). In our single-center real-world experience, the choice of the DOAC for a patient with NVAF was tailored to specific clinical features and drug pharmacokinetics of the patient. As a result, a small number of adverse events were observed.
Collapse
Affiliation(s)
- Giulia Nemola
- Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Anita Russi
- Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Gianmarco Cozzani
- Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Giulio Leo
- Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Laura Vetrugno
- Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | | | | | - Paolo Della Bella
- Arrhythmia and Electrophysiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Matteo Montorfano
- Interventional Cardiovascular Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Moreno Tresoldi
- Internal Medicine Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Anna Salerno
- Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Michela Cera
- Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Paolo Mattiello
- Data analyst, Database and Data Warehouse Specialist, San Raffaele Scientific Institute, Milan, Italy
| | - Giancarlo Comi
- Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Francesco Maisano
- Cardiac Surgery Unit, Heart Valve Center, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Alberto Zangrillo
- Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Carlo Gaspardone
- Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Francesco Melillo
- Echo Lab, Clinica Montevergine, GVM Care and Research, Mercogliano (AV), Italy
| | - Alberto Margonato
- Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Cosmo Godino
- Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; Heart Valve Center, IRCCS San Raffaele Scientific Institute, Milan, Italy.
| |
Collapse
|
2
|
Song X, Li B, Meng J, Lu W. Continuous nursing effect of senile coronary heart disease complicated with digestive tract hemorrhage. Minerva Gastroenterol (Torino) 2022; 68:361-363. [PMID: 34694094 DOI: 10.23736/s2724-5985.21.03028-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Xiaojuan Song
- Department of Functional Examination, Zaozhuang Municipal Hospital, Zaozhuang, China
| | - Beihua Li
- Department of Cardiology, Zaozhuang Municipal Hospital, Zaozhuang, China
| | - Juanjuan Meng
- Department of Geriatric Endocrinology, Zaozhuang Hospital of Traditional Chinese Medicine, Zaozhuang, China
| | - Wei Lu
- Department of Cardiology, Zaozhuang Municipal Hospital, Zaozhuang, China -
| |
Collapse
|
3
|
Clinical features and outcomes of patients in different age groups with non-valvular atrial fibrillation receiving oral anticoagulants. IJC HEART & VASCULATURE 2022; 40:101009. [PMID: 35372665 PMCID: PMC8968574 DOI: 10.1016/j.ijcha.2022.101009] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Revised: 03/08/2022] [Accepted: 03/16/2022] [Indexed: 11/22/2022]
Abstract
Background Patients with non-valvular atrial fibrillation (NVAF) need prophylactically antithrombotic therapies to reduce the risk of stroke. We hypothesized that the prognostic benefits of prophylactic antithrombotic therapies outweighed the bleeding risk among very elderly (≥85 years old) patients. Methods We analyzed clinical characteristics and outcomes of patients with NVAF in different age groups who had received different prophylactic antithrombotic therapies. We enrolled 3895 consecutive NVAF patients in the Macau Special Administrative Region (Macau SAR) of China from January 1, 2010, to December 31, 2018. Among 3524 patients [including 1252 (35.53%) very elderly patients] who completed the entire study, 2897 (82.21%) patients had a CHA2DS2-VASc score ≥ 2, 2274 (64.53%) had HAS-BLED score < 3, and 1659 (47.08%) had both of the above. The follow-up time was 3.80 (median, interquartile range 1.89–6.56) years. The primary outcome was the first occurrence of ischemic stroke, major bleeding, clinically relevant non-major gastrointestinal bleeding (CRNM-GIB), and all-cause mortality. Results A total of 2012 patients (57.09%) received no antithrombotic (NAT), 665 (18.87%) received antiplatelet (AP) agents, 371 (10.53%) received vitamin K antagonist (VKA), and 476 (13.51%) received non-vitamin K antagonist oral anticoagulants (NOACs). Eventually, 610 (17.31%) patients experienced thromboembolic events, with 167 (4.74%) strokes and 483 (13.71%) transient ischemia attack (TIA)/strokes. Bleeding events occurred in 614 (17.42%) patients, with 131 (3.72%) major bleeding, 381 (10.81%) CRNM-GIB and 102 (2.89%) minor bleeding events. All-cause deaths occurred in 483 (13.71%) patients. Compared with patients receiving NAT, patients receiving NOACs and VKA had fewer strokes (hazard ratio [HR]: 0.038; 95 %CI 0.004–0.401; p = 0.006 and HR: 0.544; 95 %CI 0.307–0.965; p = 0.037, respectively), and lower all-cause mortality (HR: 0.270; 95 %CI 0.170–0.429; p < 0.001 and HR: 0.531; 95 %CI 0.373–0.756; p < 0.001, respectively). Of note, very elderly patients with NVAF receiving NOACs had fewer strokes (adjust hazard ratio [adjHR]: 0.042; 95 %CI 0.002–1.003; p = 0.050) and lower all-cause mortality (adjHR: 0.308; 95 %CI 0.158–0.601; p = 0.001). Meanwhile, despite higher CRNM-GIB events (adjHR: 1.736; 95 %CI 1.042–2.892; p = 0.034), major bleeding events (adjHR: 1.045; 95 %CI 0.366–2.979; p = 0.935) did not significantly increase. VKA neither reduced strokes (adjHR: 1.015; 95 %CI 0.529–1.948; p = 0.963), nor improved all-cause mortality (adjHR: 0.995; 95 %CI 0.641–1.542; p = 0.981) in very elderly patients with NVAF. Conclusions Antithrombotic treatment (VKA and NOACs) reduces stroke and improves prognosis in patients in different age groups with NVAF. The prognostic benefits of NOACs outweigh their bleeding risks in very elderly patients with NVAF.
Collapse
|